Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | AHCY | P23526 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969423 | 1.00 | CYP3A4 (0.62) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL2578605 | 0.87 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL2582709 | 0.87 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL20302996 | 0.83 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL28928320 | 0.82 | CYP3A4 (0.66) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| Hydrochloric Acid SCHEMBL19603087 | 0.82 | CYP3A4 (0.66) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL29930426 | 0.82 | CYP3A4 (0.66) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL28394183 | 0.81 | CYP3A4 (0.65) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL19229982 | 0.81 | CYP3A4 (0.65) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL15788415 | 0.79 | CYP3A4 (0.78) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780348-B1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | LAURUS LABS PRIVATE LTD (IN) | 2017-03-01 | — | — | EP | disclosed |
| US-9056882-B2 | Process for the preparation of tenofovir | LAURUS LABS PRIVATE LTD. (IN) | 2015-06-16 | — | — | US | disclosed |
| US-20140303368-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | LAURUS LABS PRIVATE LIMITED (IN) | 2014-10-09 | — | — | US | disclosed |
| EP-2780348-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | Laurus Labs Private Limited (IN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072745-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | LAURUS LABS PRIVATE LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303368-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | SAMHD1, NUDT1, TYMP | CYP3A4 89/4885ADORA2A 2741/4885ADORA1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.